The research library

Maiken Nedergaard ↗ DOI's lab (2012) discovered that the brain has its own waste-clearance network — the glymphatic system — that primarily activates during sleep. Cerebrospinal fluid flushes through perivascular spaces, sweeping out metabolic waste including amyloid-beta and tau proteins — the same proteins that accumulate in Alzheimer's disease. In a 2026 randomized crossover trial in 39 participants, glymphatic clearance during normal sleep significantly increased morning plasma clearance of Alzheimer's biomarkers compared to sleep deprivation.

Not all sleep is equal. Deep slow-wave (NREM) sleep drives the strongest glymphatic clearance. As we age, slow-wave sleep becomes harder to achieve — which may explain why age-related cognitive decline accelerates after 60. Even a single night of sleep deprivation increases amyloid-beta burden measurable by PET scan in young, healthy people.

Matthew Walker's synthesis of 800+ sleep studies: sleeping 6 hours or fewer for 10 days produces cognitive impairment equivalent to 24 hours total sleep deprivation — yet subjects report feeling only slightly sleepy. Chronic sleep debt is invisible to the sufferer. REM sleep specifically governs emotional regulation, creativity, and long-term memory consolidation.

In 60,977 UK Biobank adults who wore a wrist accelerometer for 7 days (mean age 62.8, 55% female), more regular night-to-night sleep and wake timing was associated with a 20-48% lower risk of death from any cause across the four most-regular fifths of the group compared with the least regular fifth, over a mean 6.3 years of follow-up. For the most regular fifth specifically, the fully adjusted estimate was 30% lower risk of death from any cause (HR 0.70, 95% CI 0.59-0.83). Regularity was a stronger predictor of all-cause mortality than sleep duration was. This is an observational cohort, so it shows an association, not proof that fixing your schedule extends life — and the participants were older adults and 97.2% white, so it may not transfer cleanly to younger or more diverse people.

A systematic review and meta-analysis of 27 studies in healthy adults found that alcohol before bed was associated with a delayed onset of REM sleep and less REM sleep overall. The disruption showed up at low doses — 0.5 g/kg or less, roughly two standard drinks or fewer — and progressively worsened as the dose went up. Only high doses (0.85 g/kg or more, roughly five drinks) shortened the time it took to fall asleep, and the authors note this likely makes the later REM disruption worse. Effects on total sleep time, sleep efficiency and time awake after falling asleep were too uncertain to call. So the nightcap that gets you under faster is the same dose that costs you the most REM.

In a randomised, double-blind, placebo-controlled crossover trial, 12 healthy adults took a fixed 400 mg dose of caffeine — what the authors call a moderate dose, roughly four home-brewed cups and less than one large coffee-shop serving — at bedtime, 3 hours before bed, or 6 hours before bed. Measured by a validated portable sleep monitor, all three timings significantly cut total sleep time compared with placebo, by 1.1 to 1.2 hours, including the dose taken a full 6 hours before lights out. The catch is that at the 6-hour timing only the monitor caught it: participants' own sleep diaries showed a 41-minute loss that did not reach significance, meaning they slept meaningfully worse without noticing. The authors concluded the size of the reduction in total sleep time supports the standard advice to stop caffeine at least 6 hours before bed. This is a single small trial in 12 habitual caffeine users at one fixed dose, so your own threshold may sit somewhere different.

The largest sauna longevity study: 2,315 Finnish men followed for 20 years. Men using sauna 4–7 times per week had a 40% lower risk of all-cause mortality and a 50% lower risk of cardiovascular mortality compared to once-weekly users. The dose-response relationship was linear — more sessions, greater protection. These associations held after controlling for all cardiovascular risk factors. This is observational: frequent users may differ from infrequent ones in ways the adjustment did not capture. (The dementia and Alzheimer's figures often quoted alongside these come from a separate paper on the same cohort — see the dementia entry below, which cites it directly.)

Sauna use at 163°F (73°C) robustly activates heat shock proteins (HSPs), molecular chaperones that repair damaged proteins and prevent the misfolding associated with neurodegeneration. HSP70 specifically has been shown to prevent protein aggregation in Alzheimer's disease models. The protective effects persist for 24–48 hours post-session. HSPs also protect against muscle atrophy — making sauna a recovery tool with anti-sarcopenic effects.

Charles Raison's landmark JAMA Psychiatry (2016) RCT: a single session of whole-body hyperthermia (core temp raised to 38.5°C — equivalent to vigorous sauna) produced significant antidepressant effects in major depressive disorder compared to sham treatment. Improvements persisted for six weeks after a single session. The mechanism: heat stress activates IL-6 pathways that modulate mood circuits, and elevates beta-endorphins. This is an early-stage finding (n=34) and should not be interpreted as a replacement for professional mental health treatment — but it is the first randomised controlled evidence that heat exposure produces measurable, sustained antidepressant effects.

In a Finnish cohort of 2,315 middle-aged men followed for a median of 20.7 years, frequent sauna bathing was associated with lower rates of dementia and Alzheimer's disease. Compared with men who had one sauna session per week, those with 4–7 sessions per week had a hazard ratio of 0.34 for dementia (95% CI 0.16–0.71) and 0.35 for Alzheimer's (95% CI 0.14–0.90) — roughly a third the rate of the once-a-week group. At 2–3 sessions per week the association was smaller and not statistically significant (HR 0.78, 95% CI 0.57–1.06). This is observational, so it cannot show that sauna use caused the difference, and frequent users may differ from infrequent ones in ways the adjustment did not capture. The cohort was Finnish men aged 42–60 only.

A clinical review in the American Journal of Medicine concluded that sauna bathing is well tolerated by most healthy adults and children, but named specific contraindications: unstable angina pectoris, recent myocardial infarction, and severe aortic stenosis. It reported that sauna bathing is generally safe for most people with coronary heart disease who have stable angina or an old myocardial infarction, and that very few heart attacks and sudden deaths occur in saunas. It also reported that drinking alcohol during sauna bathing increases the risk of hypotension, arrhythmia and sudden death and should be avoided — no alcohol in the sauna. If any of those heart conditions apply to you, talk to your doctor before your first session. This is a narrative review rather than a trial, and it is now 25 years old, so it reflects the evidence available at the time.

A prospective cohort of 1,935 Finnish men aged 42-61 was followed for a median of 25.6 years, and more frequent sauna bathing was associated with fewer hospital-diagnosed respiratory conditions — COPD, asthma, or pneumonia. Compared with men having one sauna a week or fewer, those having 2-3 were about 27% less likely to be hospitalised with one of these (hazard ratio 0.73), and those having 4 or more were about 41% less likely (0.59). For pneumonia specifically, the 2-3 per week figure was similar (0.72), but the estimate for 4 or more (0.63) did not reach statistical significance — its confidence interval touched 1.00. This is observational work in middle-aged white Finnish men and cannot show cause; men already developing lung disease may simply have used the sauna less. If you have a diagnosed lung condition, ask your doctor before starting regular sauna sessions.

Every entry above is men only. Two later papers from the same Finnish cohort brought women in. In 1,688 people aged 53–74, just over half of them women, 4–7 sauna sessions a week compared with one was associated with a 70% lower rate of cardiovascular death (hazard ratio 0.30, 95% CI 0.14–0.64; 0.23 after full adjustment), and in 1,628 people without a prior stroke the same frequency was associated with a 61% lower rate of stroke (0.39, 0.18–0.83). In both papers the association was reported as not differing by sex. Read that carefully: the women's own high-frequency groups were small — too few events to estimate on their own — so the finding is demonstrated in men and not contradicted in women, at the same 4–7 sessions a week. No paper supports a lower target for women; this app used to carry one, and it has been removed. Observational, single baseline questionnaire, East-Finnish and white.

A prospective US cohort of 23,491 pregnant women found that heat exposure in early pregnancy from sauna, hot tub or fever, taken together, was associated with about twice the risk of a neural tube defect (relative risk 2.2, 95% CI 1.2–4.1). Sauna on its own did not reach statistical significance in that cohort; the signal was carried mostly by hot tubs and fever. A meta-analysis of fifteen studies of maternal hyperthermia in early pregnancy — mostly fever — found a pooled relative risk of 1.95 (1.30–2.92) across its cohort studies. Neither source shows that sauna itself is harmful, but both point the same way about heat in the first trimester. If you are pregnant or trying to be, ask your doctor before sauna, and treat the first trimester as the time to skip it.

Across 122,007 adults, higher cardiorespiratory fitness showed an inverse, no-upper-limit association with all-cause mortality. The most important finding: going from the bottom 25th percentile ("low") to just above average (50th–75th percentile) is associated with a 70% reduction in all-cause mortality. From low to below-average alone yields a 50% reduction. This jump — from sedentary to merely above-average — is achievable by almost anyone in 3–6 months of consistent Zone 2 training.

VO₂ max training triggers PGC-1α, the master regulator of mitochondrial biogenesis. More mitochondria per muscle cell means greater metabolic efficiency, reduced reactive oxygen species production, and slower cellular aging. San-Millán & Brooks linked the lactate-stable Zone 2 intensity to fat oxidation and mitochondrial efficiency; polarized-training research (Seiler) is the basis for ~80% low-intensity volume.

Aerobic exercise is the most potent non-pharmacological activator of BDNF (brain-derived neurotrophic factor) — the protein that drives neuroplasticity and adult neurogenesis. A single aerobic session raises BDNF 2–3× above baseline. Chronic aerobic training is associated with measurable increases in hippocampal volume — the brain region first affected by Alzheimer's — reversing age-related hippocampal shrinkage.

481 sedentary adults from 98 two-generation families completed the same supervised 20-week cycle-ergometer program. The average VO2max gain was about 400 ml/min, but the spread was enormous: some participants gained little or nothing while others gained more than 1,000 ml/min. There was 2.5 times more variance in response between families than within them, and model-fitting estimated the maximal heritability of the training response at 47%. This was a large single-arm training study rather than a randomised trial — there was no control group — and all participants were sedentary white adults, so the exact figures may not transfer to everyone. Heritability describes how much of the variation across this group tracked with family; it does not predict any one person's ceiling.

1,567 Norwegians aged 70 to 77 were randomised for five years to twice-weekly 4x4 intervals at roughly 90% of peak heart rate, moderate continuous training at roughly 70%, or the national physical activity guidelines. The primary result was null: combined supervised training showed no all-cause mortality benefit over the guideline group. Within that, the interval group's mortality was lower than control (hazard ratio 0.63, 95% CI 0.33 to 1.20) and lower than the moderate group (hazard ratio 0.51, 95% CI 0.25 to 1.02), but both confidence intervals cross 1.0, so these are trends rather than demonstrated effects. Read the null carefully: the control group was not sedentary — four in five participants were already moderately or highly active at baseline, and the authors report that controls did enough high-intensity work on their own to land at an exercise dose between the two supervised groups. Only 4.7% of controls died in five years, leaving little room for any difference to show, so this is a null against an active comparator, not evidence that training does nothing. If you are older or managing a heart condition, check with your doctor before starting intervals at this intensity.

San-Millán & Brooks characterized the lactate-based intensity zones and "metabolic flexibility" — fitter individuals oxidize more fat at a given lactate. Zone 2 (lactate production ≈ clearance) is associated with high fat oxidation and mitochondrial efficiency. Elite endurance athletes spend ~80% of volume at low intensity (Seiler). The associated adaptations — fat oxidation, insulin sensitivity, mitochondrial density — track with metabolic-health and longevity biomarkers.

Zone 2 training is the most potent non-pharmacological intervention for insulin sensitivity. Regular low-intensity aerobic exercise reduces visceral fat, improves glucose uptake via GLUT4 upregulation, and suppresses pro-inflammatory cytokines (TNF-α, IL-6 at rest). The anti-inflammatory effect persists chronically — trained athletes have fundamentally lower inflammatory baselines than sedentary individuals at the same body weight.

The minimum effective dose for longevity benefits: 150 minutes per week of moderate-intensity aerobic activity (Zone 2 equivalent), per WHO guidelines and backed by the physical activity guidelines cohort data. This is the threshold below which mortality risk reduction is minimal; above which benefits plateau relatively quickly. The quality of those 150 minutes — staying in true Zone 2 — matters more than total duration.

Forty-eight well-trained runners, cyclists, triathletes and cross-country skiers were randomly assigned for nine weeks to one of four intensity mixes — high-volume easy, threshold, HIIT-only, or polarised (mostly easy plus a block of genuinely hard work) — and 41 finished. The polarised group gained the most VO₂peak: 6.8 ml/kg/min, about 11.7%, along with 17.4% more time to exhaustion. HIIT-only improved on both as well, just by less (VO₂peak +4.8%, time to exhaustion +8.8%), while threshold and high-volume easy improved on neither — threshold VO₂peak actually fell 4.1%. Two cautions: on time to exhaustion the four groups did not differ significantly from each other, so the ranking is softer than the headline number looks; and the polarised arm here was about 68% easy, 6% threshold, 26% hard — closer to 70/30 than to a literal 80/20, which comes from Seiler's observational work rather than from this trial. One small nine-week study in already-trained athletes split four ways, roughly ten per group — suggestive rather than settled, and it says nothing about beginners.

A pooled analysis of 270 randomised trials covering 15,827 participants found resting blood pressure fell after every mode of exercise training studied. Aerobic training was associated with reductions of about 4.5/2.5 mmHg and high-intensity intervals about 4.1/2.5 mmHg — strikingly similar. When the five modes were ranked for systolic pressure, isometric work such as wall sits placed first (98.3%, about 8.2/4.0 mmHg) and combined aerobic-plus-resistance training second (75.7%); aerobic training placed fourth (40.5%) and intervals last (39.4%), essentially tied. Those rankings come from indirect network comparisons, which are weaker evidence than direct head-to-head trials. If you are being treated for high blood pressure, talk to your doctor before changing anything about your medication.

After 40, the muscle protein synthesis response to dietary protein is blunted — a phenomenon called anabolic resistance. Multiple isotope tracer studies show that adults over 60 require 1.2–1.6g of protein per kilogram of bodyweight per day just to prevent negative protein balance — 50%+ more than the 0.8g/kg RDA. Gabrielle Lyon synthesizes this research into a practical target: 1g of protein per pound of ideal bodyweight (2.2g/kg) for active adults, with at least 30–50g per meal to overcome the leucine threshold for protein synthesis signaling.

Skeletal muscle is the largest site of glucose disposal, the primary producer of myokines (including irisin and IL-6 post-exercise), and the major determinant of resting metabolic rate. Sarcopenia — age-related muscle loss — drives insulin resistance, increases fall and fracture risk, and is independently associated with all-cause mortality. Every decade after 30, untreated adults lose 3–8% of muscle mass. This is not inevitable — it is a protein and resistance training deficit.

The key amino acid for muscle protein synthesis is leucine — it directly activates mTORC1, the master regulator of muscle protein synthesis. A minimum of 2–3g of leucine per meal is required to trigger the anabolic response. Animal proteins (meat, eggs, dairy) typically provide this threshold at 30–50g portions. Plant proteins require larger portions or combining to achieve equivalent leucine delivery. The timing around resistance training (within 2 hours) amplifies the synthesis signal 2–3× above fasted conditions.

Stokes et al. (Nutrients, 2018) reviewed dietary protein for muscle hypertrophy with resistance training: spreading sufficient high-quality protein across 3–4 meals per day — each meeting the per-meal leucine threshold — maximises the muscle protein synthesis response and underpins preservation of lean mass with age.

A meta-analysis of 49 randomised controlled trials in 1,863 healthy adults doing at least six weeks of resistance training found that protein supplementation added a small but real amount on top of the training itself: 0.30 kg of fat-free mass and 2.49 kg on one-rep-max strength. A breakpoint analysis placed the point of diminishing returns at a total protein intake of about 1.62 g/kg/day — past that, extra supplemental protein produced no further gains in fat-free mass. That estimate is imprecise, though: its 95% confidence interval ran from 1.03 to 2.20 g/kg/day, and the authors suggested ~2.2 g/kg/day as the prudent target for anyone wanting to maximise gains. The fat-free-mass benefit of supplementing shrank with increasing age and was larger in people already resistance-trained. This looked at supplements added on top of habitual eating, so it describes where extra protein stops helping rather than a universal requirement.

A systematic review of 43 randomised trials, 30 of them pooled, compared plant with animal protein for muscle outcomes. Plant protein was associated with slightly lower muscle mass after the intervention than animal protein (standardised mean difference -0.20, 95% CI -0.37 to -0.03), with the gap seen in adults under 60 and not statistically detectable in those 60 and over, and showing up only in trials that paired protein with resistance training. Soy versus milk protein showed no pooled difference; the gap came from non-soy plant proteins — rice, chia, oat and potato — and from whole plant-based diets. Overall muscle strength and physical performance showed no difference, though animal protein did edge out plant protein for lower-body strength in the over-60s specifically. The authors describe the effect as small, note substantial variation between trials, and say a wider range of plant proteins still needs testing.

Blake, Galpin and colleagues (J Int Soc Sports Nutr, 2025) randomised 17 well-trained adults — roughly 8 to 9 per group — to either a 16:8 time-restricted eating window or normal all-day feeding, while training four times a week for 8 weeks on a 10% calorie surplus with protein at 2.2 g/kg/day. Both groups gained strength, muscular endurance and fat-free mass. The time-restricted group completed less total training volume and gained 4.0 ± 1.9 kg less on squat 1RM (p = 0.05, borderline), and reported lower daily energy at week 4. Fat-free mass gains numerically favoured the time-restricted group (2.67 against 1.82 kg), while all-day feeding added 1.4 ± 0.6 kg more fat. The authors conclude 16:8 is viable during a building phase when calories and protein are adequate. With 17 people in total, this applies to well-trained young adults on a supervised surplus and should not be stretched further.

Leong et al. (Lancet, 2015) across 139,691 participants in 17 countries: grip strength was more strongly associated with cardiovascular mortality and all-cause mortality than systolic blood pressure. A 5kg decrease in grip strength was associated with a 17% higher risk of cardiovascular mortality and a 16% higher risk of all-cause mortality. The mechanism: grip strength reflects the integrated health of the entire musculoskeletal system, neuromuscular integrity, and — critically — vascular health.

Multiple recent studies document a strong association between grip strength and cognitive outcomes. Handgrip strength is associated with learning and verbal fluency in older men without dementia (Prokopidis et al., GeroScience, 2023 ↗ DOI). The mechanism is vascular: the same small vessel disease that reduces peripheral muscle perfusion and force production also reduces cerebral perfusion. Grip strength is a window into the brain's blood supply. Building grip strength likely protects both systems simultaneously.

The Leong data measured grip strength as an outcome, not a training modality. The exercises that build grip strength — dead hangs, farmer's carries, thick-bar pulling — develop the hand and forearm musculature, wrist stability, and tendon strength. Tendon adaptation is slow: minimum 12–16 weeks of consistent load to see structural changes. The dose: 3 sessions per week with progressive load. Dead hangs for time, farmer's carries for distance, plate pinches for isolated finger flexor development.

This study pooled 60,803 grip measurements from 49,964 people across twelve British general-population studies to build reference centile curves spanning ages 4 to 90. Grip rises to a peak in early adulthood, holds through midlife, then declines: peak median grip was 51 kg for men and 31 kg for women, reached between ages 29 and 39 in men and between 26 and 42 in women. Weak grip — at least 2.5 standard deviations below the sex-specific peak mean — increased sharply with age, reaching 27% of women and 23% of men by age 80. Sensitivity analyses found the curves held up regardless of dynamometer type and whether the person was seated or standing. These are cross-sectional centiles from British populations, so they tell you where a reading sits in a distribution at a given age, not what will happen to any individual. The authors present them as values with the potential to inform clinical assessment of sarcopenia and frailty, so if your number looks low for your age, take it to a clinician rather than reading it as a diagnosis.

Sara Lazar (2005) MRI study: 8 weeks of MBSR (Mindfulness-Based Stress Reduction) produces measurable thickening of the prefrontal cortex, insula, and anterior cingulate cortex. These are the regions governing attention, interoception, and emotional regulation. The thickness correlates with years of practice — long-term meditators have the same prefrontal cortex thickness as people 20 years younger. Wendy Suzuki (NYU, 2021) demonstrated that a single 20-minute meditation session improves sustained attention, working memory, and cognitive flexibility for 24+ hours.

Non-Sleep Deep Rest (NSDR) — Yoga Nidra, body-scan, and similar guided-relaxation protocols — reliably shifts the autonomic nervous system toward parasympathetic "rest-and-digest" dominance. In a randomized trial, a single Yoga Nidra session significantly raised heart rate variability, a marker of vagal (parasympathetic) tone. The popular claim that NSDR "restores depleted dopamine" by roughly 65% is not an established effect: it traces to a single unreplicated PET study (n=8) that measured a transient rise in striatal dopamine during the practice — tied to reduced readiness for action, not a lasting refill of reserves or a motivation boost afterward. Treat NSDR as a fast, evidence-supported route to calm and recovery, not as a dopamine refill.

Mindfulness meditation reduces levels of NF-κB — the master regulator of the inflammatory response — and pro-inflammatory cytokines (IL-6, TNF-α). A 2016 RCT showed that a 3-day mindfulness retreat produced measurable changes in inflammatory gene expression persisting for one month. Meditation practitioners also show significantly longer telomere length and higher telomerase activity — suggesting epigenetic anti-aging effects.

The most rigorous appraisal of the field found the benefits real but modest. After screening 18,753 citations, it included 47 randomized trials with 3,515 participants. Against active controls designed to match placebo and attention effects, mindfulness meditation showed small-to-moderate improvements in anxiety (effect size 0.38, 95% CI 0.12-0.64, at 8 weeks, fading to 0.22 by 3-6 months) and depression (0.30, 95% CI 0.00-0.59, at 8 weeks) — those individual estimates come from subsets of the trials, not all 47, and the depression range reaches down to zero. The authors reported no evidence that meditation programs were better than any active treatment, including drugs, exercise and other behavioural therapies, and low or insufficient evidence of any effect on positive mood, attention, substance use, sleep, eating habits or weight. If you are weighing meditation against or alongside treatment for anxiety or depression, that is a conversation for your clinician.

A systematic review of 83 studies covering 6,703 meditators found that adverse events during or after practice are not uncommon. Pooled prevalence was 8.3%, but it varied sharply by study design: 3.7% in experimental studies versus 33.2% in observational ones. The authors judge that randomised trials likely under-report these events, since most never assess them at all, though the observational practitioners were also meditating in less structured settings, so the two groups may differ in more than whether anyone asked. The most commonly reported effects were anxiety, depression, and cognitive anomalies such as confusion or disorientation, and among the case reports most people had no prior mental health history. For context, the authors place 8.3% alongside the 3–10% rate reported for psychotherapy in general. If meditation is leaving you persistently anxious or disoriented, that is worth raising with a clinician.

An updated meta-analysis pooled 45 randomized trials of mindfulness delivered through a smartphone app rather than in person. Against control groups, apps were associated with small but statistically reliable reductions in depression and anxiety symptoms (depression Hedges g = 0.24, 95% CI 0.17–0.31; anxiety g = 0.28, 95% CI 0.21–0.35), and the effect held when the analysis was restricted to the larger and lower-risk-of-bias trials. Two limits come with that. Trials comparing apps against active therapeutic treatment found no significant difference in either direction (g = −0.15 for depression, g = 0.10 for anxiety), but there were only three to four such comparisons — far too few to conclude that an app matches therapy. Symptoms were also measured only at the end of each program, and the authors note that the shortage of longer-term follow-up leaves it an open question whether the benefit lasts. If you are being treated for depression or anxiety, treat an app as an addition to that care and talk to your clinician before changing anything.

Fahey & Talalay (PNAS, 1997): broccoli sprouts contain 50–100× more sulforaphane precursor than mature broccoli. Sulforaphane is the most potent naturally occurring activator of NRF2 — the master regulator of the cellular antioxidant and detoxification response. NRF2 activation turns on genes that neutralize carcinogens, excrete benzene and BPA, and produce glutathione (the brain's primary antioxidant). Critically: sulforaphane activates the same detoxification pathways that may protect against microplastics — now found in human blood, lungs, and brain tissue. Target: 30–100mg sulforaphane daily from broccoli sprouts or standardized extract.

Dr. William Harris (Nature Communications, 2021) pooled 17 prospective cohort studies: higher blood omega-3 levels correlate with significantly lower all-cause mortality. The key metric: the Omega-3 Index — EPA+DHA as a percentage of red blood cell membrane fatty acids. Target ≥8%. In Japan, average Omega-3 Index is ~9–10% and life expectancy is 5 years longer than the US average of ~5%. A low Omega-3 Index is as strong a predictor of early death as smoking. The dose needed to reach ≥8%: typically 2–4g EPA+DHA daily. Test your index (finger-prick test, ~$50) — most people are far below target even with supplementation.

Urolithin A (UA) is produced by gut bacteria from pomegranate and berry ellagitannins. Liu et al. (JAMA Network Open, 2022) RCT of 66 older adults: 1,000mg UA produced significant improvement in muscle endurance and mitochondrial health biomarkers compared to placebo. A 2025 Nature Aging RCT showed UA expanded naïve T cells and improved immune metabolic function — reversing age-related immune decline. Critically: ~40% of adults cannot produce UA from food due to gut microbiome composition. Supplementation with a standardised urolithin A supplement (1,000mg) is the reliable route for this population.

Curcumin (500mg with piperine for bioavailability): Hewlings & Kalman (2017) review — anti-inflammatory via NF-κB suppression, and in knee osteoarthritis RCTs curcumin extracts performed comparably to ibuprofen for pain, with fewer gastrointestinal complaints reported in the curcumin groups than the NSAID groups — fewer, not none. Berries (anthocyanins): the human evidence is vascular and modest. In a 6-month double-blind trial in 115 adults with metabolic syndrome, one cup of blueberries a day — 150g fresh weight, given as 26g of freeze-dried powder — improved flow-mediated dilation by 1.45 percentage points (95% CI 0.83–2.1), while half a cup did nothing and the trial's own primary endpoint, insulin resistance, was unchanged (Curtis et al., 2019). Flow-mediated dilation is a laboratory measure of blood-vessel flexibility, not a health outcome — no heart attacks or strokes were counted. Separately, higher habitual anthocyanin intake was associated with lower risk of nonfatal heart attack across 24 years in 43,880 men (Cassidy et al., 2016), which is cohort data: association, not cause. The cognitive claim commonly made for blueberries is not supported in people without existing decline — a 6-month trial found no effect on cognition, mood, alertness or sleep (Curtis et al., 2024). Garlic: blood pressure is the only one of the usual garlic claims with randomised human trials behind it. Pooling 17 trials, garlic supplements were associated with systolic pressure about 3.8 mmHg lower (95% CI 2.5–5.0), and about 4.4 mmHg lower in participants who were already hypertensive (Wang et al., 2015) — trials consistently find no reduction in people whose blood pressure is already normal, and effect sizes shrink as trial quality rises. That is a surrogate measure: whether garlic prevents a heart attack or a death is untested, and a Cochrane review looking for exactly that found two eligible trials totalling 87 patients (Stabler et al., 2012). The "16–40% lower cardiovascular risk" quoted alongside garlic is arithmetic projected from blood-pressure epidemiology, not events anyone counted. Cholesterol and immunity are weaker still: six months of raw, powdered or aged garlic at about a clove a day moved LDL by under 4 mg/dL in every arm including placebo, with no significant difference between them (Gardner et al., 2007), and Cochrane concluded that claims for the common cold "appear to rely largely on poor-quality evidence" (Lissiman et al., 2014). Worth knowing that the review long cited for garlic argues allicin is not the active constituent at all — written by an author employed by a manufacturer of allicin-free aged garlic extract (Amagase, 2006). If you take a blood thinner, run any garlic supplement past your doctor first.

A Lancet series of systematic reviews and meta-analyses pooled 185 prospective studies and 58 clinical trials — just under 135 million person-years of cohort data, plus 4,635 trial participants. People eating the most dietary fibre had 15-30% lower all-cause and cardiovascular mortality, and lower incidence of coronary heart disease, stroke, type 2 diabetes and colorectal cancer, than those eating the least. Risk reduction across a range of critical outcomes was greatest at 25-29 g of fibre a day, and the dose-response curves suggested higher intakes might help further. The trials separately showed lower bodyweight, systolic blood pressure and total cholesterol at higher fibre intakes. The mortality evidence is observational, and the authors graded the certainty of the dietary fibre evidence as moderate.

Momma et al. (Br J Sports Med, 2022) — systematic review and meta-analysis, 1.7 million participants: muscle-strengthening activities were associated with a 10–17% lower risk of all-cause mortality, cardiovascular disease, cancer, diabetes, and lung cancer, independent of aerobic activity. Notably, the benefits plateaued at approximately 60 minutes per week — suggesting the minimum effective dose is achievable by almost anyone. Resistance training is not optional for longevity.

Araújo et al. (Mayo Clinic Proceedings, 2025) — 3,889 participants, 10.8-year follow-up, CLINIMEX Exercise cohort: relative muscle POWER (force × velocity) was a significantly stronger predictor of all-cause mortality than grip strength. Hazard ratio for lowest vs. highest power quartile: 5.88 in men, 6.90 in women. This is landmark data: "How fast can you lift?" is more predictive of longevity than "How much can you lift?" Muscle power declines earlier and faster than muscle strength with aging — making velocity-based training a longevity priority, not an athletic one.

Araújo's Sitting-Rising Test (SRT) — sit cross-legged to the floor and rise without using hands — assesses strength, power, balance, flexibility, and body composition simultaneously. European Journal of Preventive Cardiology (2014): SRT scores below 8/10 were associated with 2–5× higher mortality over 6 years. Scores of 0–3 carried 5–6× higher risk than scores of 8–10. Updated 2025 data confirms SRT also predicts cardiovascular-specific mortality. Try it: can you sit and rise from the floor without using your hands?

Hart & Buck (Health Promotion Perspectives, 2019) — systematic review and meta-analysis of 16 randomized controlled trials in adults aged 50+: resistance training significantly improved health-related quality of life (SF-36/SF-12), spanning physical-function and mental-health domains. Strength training is associated not just with living longer but with living better — more function, less disability, better mood with age.

A systematic review asked how little training still builds strength in men who already lift, and found six studies. In the five that could be pooled, a single set taken to failure — 6-12 reps at roughly 70-85% of one-rep max, 2-3 times a week for 8-12 weeks — produced an estimated 12.09 kg increase in overall 1RM (95% CI 8.16-16.03 kg). Pooled by lift, the estimates were 17.48 kg for the squat (95% CI 8.51-26.46) and 8.25 kg for the bench press (95% CI 0.68-15.83), with the bench figure far less certain — its lower bound sits close to zero. Across the six studies, training as little as once a week still produced significant gains, and the authors are explicit that this is "suboptimal, yet significant" — a floor, not an optimum. The evidence base is thin: six studies, all in resistance-trained men, and not all of them reported the load used. The authors say it is unclear whether the same holds for the deadlift, for trained women, or for highly trained strength athletes.

In this 8-month randomised trial, 101 postmenopausal women with low bone mass (average age 65) did either twice-weekly 30-minute supervised high-intensity resistance and impact training — 5 sets of 5 reps above 85% of one-rep max — or a home-based low-intensity program. The heavy-training group gained 2.9% in lumbar spine bone mineral density while the control group lost 1.2% (p<0.001). At the femoral neck the heavy-training group essentially held its ground (+0.3%, not a significant change on its own) while controls lost 1.9%, a between-group difference of p=0.004. Only one adverse event was reported across the whole trial — a minor lower back spasm costing two sessions — which matters because heavy lifting is conventionally discouraged in osteoporosis over fracture fear, though the trial was not powered to assess safety. This is a single trial in women screened for other conditions and medications, training under close supervision; the authors explicitly do not recommend this protocol unsupervised, and it is not evidence that unsupervised heavy lifting is safe for a fragile spine. If you have low bone density, talk to your doctor before adding heavy loading.

A meta-analysis of 13 training studies compared taking sets all the way to muscular failure against stopping a few reps short. For maximal strength there was no overall difference (SMD -0.08, p=0.642); only when training volumes were not matched between the groups did stopping short come out ahead (SMD -0.34, p=0.048). Power followed the same shape — no overall difference (SMD -0.20, p=0.239), with an edge to stopping short in the non-matched-volume comparisons (SMD -0.61, p=0.025). Training to failure was associated with more muscle growth in the overall analysis (SMD 0.75, p=0.005), but that difference disappeared once total volume was equalised, pointing to the extra work rather than the failure itself. Thirteen studies is a modest base, the review pooled randomised and non-randomised trials, the advantages for stopping short appear only in the comparisons where volume was not matched, and this analysis did not measure fatigue or injury.

A meta-analysis pooled 54 effects from 33 randomised trials covering 1,877 adults and found resistance training was associated with a moderate reduction in depressive symptoms (effect size 0.66, 95% CI 0.48-0.83, pthe mood benefit did not track strength gains. Heterogeneity was high (I² 76%), and trials with blinded allocation and/or assessment reported smaller reductions, so the true effect may be smaller than the headline figure. The authors call for better-quality trials that blind both allocation and assessment and compare resistance training against other established treatments for depressive symptoms. If you are being treated for depression, treat this as a possible addition to your care and talk to your clinician before changing anything.

Galpin and colleagues (Analytical Biochemistry, 2012) built and validated a way to measure protein content by muscle fibre type, typing 264 individual vastus lateralis fibres and then pooling them by type — about 20 fibres per pool — for quantification. The mitochondrial enzyme citrate synthase was 528% more abundant in slow MHC I fibres than in the fastest MHC IIx fibres, falling cleanly in order across the continuum. The glycolytic enzyme GAPDH ran the opposite way, up to 160% higher in fast fibres than in slow. The authors describe these as initial results indicating that proteins are distributed hierarchically across the slow-to-fast continuum — a pattern consistent with slow and fast fibres being metabolically distinct, rather than faster and slower versions of the same cell. This is a descriptive methods paper, not a test of how fibres respond to training.

Vastus lateralis biopsies from 21 elite American weightlifters — 6 World/Olympic-caliber women, 9 National-caliber women and 6 National-caliber men, with 3 Olympic Games and 19 World Championships between them — showed what Serrano, Galpin and colleagues reported in 2019 as the highest pure fast-twitch (MHC IIa) concentrations then recorded in a healthy vastus lateralis: 67 ± 13% across the group, rising to 71 ± 17% in the World and Olympic-caliber women. The authors suggest that competitive caliber and years in the sport track fibre-type percentage more closely than biological sex does. Because these were one-time biopsies of already-elite lifters, the study cannot separate how much of that profile is inborn from how much reflects years of training.

In 15 resistance-trained men, Bagley, Galpin and colleagues (J Strength Cond Res, 2017) measured peak knee-extension torque 46% higher than in recreationally active men, and a higher proportion of fast-twitch fibres — 61 ± 4% against 44 ± 4%, a gap of 17 percentage points. But the widely used Thorstensson fatigue test showed no relationship whatsoever with actual myosin heavy chain fibre type (R = 0.01), and the authors concluded it may not accurately estimate fibre-type composition in trained men. If you want to know your fibre type, a field fatigue test is not the way to find out. This is a cross-sectional comparison, so the higher fast-twitch proportion is associated with trained status rather than shown to be caused by training.

Moscow's Institute of Biomedical Problems — the cosmonaut-physiology institute — has studied lifting a moderate load "without relaxation", keeping the muscle under continuous tension rather than resting between repetitions, since a 2006 trial in young men reported strength and muscle gains from it. In ten strength-trained male athletes, a 54%-of-max session done this way produced roughly twice the blood lactate of the same load lifted normally, and that metabolic stress was associated with lower myostatin gene expression — myostatin being the brake on muscle growth. In a later study, eight trained lifters trained one leg at 65% of max and the other at 85%, both to failure: the mTORC1 signalling that drives muscle protein synthesis rose only after the moderate-load leg, which did more total work, while the heavy leg switched on a different pathway. Small, male, single-lab, and acute signalling is not the same as measured growth; the same group reports that heavy training still produced the larger gains. What it supports is that moderate loads taken close to failure are associated with the growth signal — not that they beat heavy lifting.

Alpha-actinin-3 is a protein of fast-twitch muscle fibres, and people with two copies of the ACTN3 "X" variant make none of it. In 486 Russian power athletes of regional or national standard compared with 1,197 controls, that XX genotype was less than half as common among the athletes (6.4% vs 14.2%), and rarest of all — 3.4% — among the most elite. A follow-up genotyped 1,423 Russian athletes for 15 metabolic gene variants and found a high count of "endurance" variants in 85.7% of the best endurance athletes against 37.8% of controls. The ACTN3 direction has held in every meta-analysis since, with a modest effect and some publication bias; the individual endurance variants are candidate-gene findings that have not been independently replicated and should not be read as a list of longevity genes. This is association in elite athletes, not a verdict on anyone's training: genes shape the ceiling, and the floor is what you do.

Søberg et al. (Cell Reports Medicine, 2021): habitual winter swimmers show enhanced cold-induced thermogenesis — brown adipose tissue ("brown fat") burning energy to generate heat. Separately, Šrámek et al. (2000) measured the neurochemical response to one hour of immersion at 14°C: noradrenaline rose ~530% and dopamine ~250%. Two honest caveats: that was a 1-hour laboratory exposure, not a 2–3 minute plunge (the catecholamine response is dose- and temperature-dependent), and a brief plunge produces an acute surge, not a lasting baseline shift. The catecholamine chemistry is well established but downstream mood and focus benefits are not (human RCTs are mixed). Water: 50–59°F (10–15°C); immersion beats cold showers.

The most robust cold benefit is metabolic. Adult humans retain functional brown adipose tissue (BAT) that switches on with cold — established in 2009 when three independent teams (all in NEJM) documented cold-activated BAT in adults; its activity is lower with higher age and BMI. It is also trainable: a 10-day cold-acclimation protocol raised BAT activity alongside non-shivering thermogenesis, with no sex difference (van der Lans 2013), and six weeks of repeated cold recruited BAT and reduced body fat in people who started low (Yoneshiro 2013). BAT burns glucose and fat to make heat via mitochondrial uncoupling — the mechanism behind cold's links to better glucose handling and a modest metabolic bump, and the best-supported reason to do it.

Rhonda Patrick on the anterior mid-cingulate cortex (aMCC): this region of the brain grows when you do things you dread. The more you dread something and still do it, the more the aMCC strengthens. Cold plunges and heavy training are the canonical examples. This is not metaphorical — neuroimaging studies show aMCC volume correlates with willpower, stress resilience, and perseverance across domains. Cold exposure is neurologically building the same capacity that makes everything else easier.

Critical protocol note from Fyfe et al. (2019): cold water immersion immediately after strength training blunts mTOR signaling and muscle protein synthesis — attenuating muscle-fiber (type II) hypertrophy. The vasoconstriction inhibits the muscle protein synthesis signal. Wait 4–6 hours after strength training before cold exposure. For pure cold and cardiovascular protocols: morning or fasted cold is optimal. For strength goals: cold is a separate session.

A randomised trial of 3,018 adults aged 18-65 assigned participants to finish their daily shower with 30, 60, or 90 seconds of cold water for 30 consecutive days, or to shower as usual. The cold groups showed a 29% reduction in sickness absence from work (incidence rate ratio 0.71, p = 0.003), but there was no significant difference between groups in illness days — participants reported being off work less, not being ill less. 79% completed the full 30 days, and no related serious adverse events were reported. The trial was unblinded and both outcomes were self-reported, which limits how firmly the absence result can be read. Everyone enrolled was free of severe existing illness, so if you have a heart condition, ask your doctor before starting cold exposure.

Cold water submersion can produce a high incidence of cardiac arrhythmias — irregular heartbeats — even in healthy volunteers. Going under, and releasing a held breath, can fire two powerful and antagonistic responses at the same time: the cold shock response, a sympathetically driven tachycardia that speeds the heart up, and the diving response, a parasympathetically mediated bradycardia that slows it down. The authors call that strong and simultaneous activation of both limbs of the autonomic nervous system autonomic conflict, and propose it may account for those arrhythmias and may, in some vulnerable individuals, be responsible for deaths previously wrongly ascribed to drowning or hypothermia. This is a proposed mechanism argued from existing evidence, not a finding from a single trial, and the authors present it as a hypothesis. If you have a heart condition or a history of arrhythmia, talk to your doctor before cold plunging.

Galpin and colleagues (Sports, 2016) had 13 participants complete three cycling trials, each two 5-minute high-intensity bouts plus a time-to-exhaustion test, applying wet ice, menthol spray or nothing to the back of the neck during the one-minute rest intervals. Against no treatment, ice lowered thermal sensation after both rest intervals and through recovery, and lowered perceived exertion after the second bout; against menthol spray, it lowered neck and chest skin temperature after the first rest interval. Time to exhaustion did not change at all (68.9 ± 18.9 s). The honest headline is that null: intermittent neck icing improved how hard the work felt without improving what was measured. Small single-lab protocol, 13 participants.

Gillen et al. (PLOS ONE, 2016): 3 sessions of 3×20-second all-out sprints per week (10 minutes of work per session) produced equivalent cardiovascular and metabolic adaptations to 150 minutes of moderate exercise. The mechanism: supramaximal effort (>100% VO₂ max) recruits all muscle fiber types including fast-twitch Type IIx fibers that Zone 2 training never reaches. These fibers have the highest glycolytic capacity, highest power output, and most significant mitochondrial adaptation potential when trained at true maximum intensity.

The Araújo 2025 Mayo Clinic Proceedings data (see also: Strength arm) directly supports sprint training as a longevity intervention. Muscle power — force times velocity — was associated with substantially higher mortality risk in the lowest quartile — a stronger association than grip strength showed in the same analysis in men. Sprints train exactly this quality: rapid recruitment of high-threshold motor units, maximum rate of force development, neuromuscular coordination at high velocity. A training program that includes sprints builds the velocity component of fitness that traditional gym training misses.

Intervals work for women; the uncertainty is in the dials, not the payoff. The review dedicated to low-volume interval training in women reports that HIIT and sprint interval training consistently improve cardiorespiratory fitness in women, and that most sex-based comparisons show similar improvements in women and men. What is thinner is everything downstream of that: the same review describes the research on insulin sensitivity and skeletal-muscle mitochondrial response in women as limited and conflicting, with some evidence of blunted improvements relative to men. Two things often repeated as female-specific rules are not established. On ageing — a study that measured both capacities in the same 37–90-year-old master athletes found peak anaerobic and peak aerobic power declined at a similar rate, roughly 7–14% per decade, and that this did not differ between athletic disciplines or sexes (Bagley et al., 2019 ↗ PubMed). On recovery length — the one trial that compared recovery periods by sex found the reverse of the usual advice: females, but not males, improved average high-intensity running speed and speed decrement on 30-second recoveries rather than 180-second ones, and its authors conclude that female- and male-specific protocols still need to be established (Schmitz et al., 2020 ↗ PubMed). Both are small studies. Train intervals — and treat any sex-specific interval prescription, including one you read here, as untested.

A systematic review of 188 studies (8,928 participants) asked how reliably adults who were insufficiently active or living with a medical condition completed high-intensity intervals versus moderate continuous training. In supervised programs, attendance averaged 89.4% for intervals and 92.5% for moderate training, and across the 65 studies that ran both, the difference was not statistically significant (p = 0.78) — evidence the authors rate moderate-certainty. A separate, much smaller set of studies looked at unsupervised training and found far lower completion: 63% for intervals and 68.2% for moderate. The 10 studies comparing those two also found no significant difference, though a non-significant trend favoured moderate training (p = 0.10), and the authors rate this half of the evidence very low certainty and say it should be read with caution. Because the supervised and unsupervised figures come from different studies measuring different things, the lower unsupervised numbers show that unsupervised training is less consistently completed in general — not that a given person's attendance drops when supervision is removed.

Rider et al. (European Urology, 2016) followed 31,925 men for 18 years: those who ejaculated 21+ times per month had a hazard ratio of 0.81 (95% CI 0.72–0.92) for prostate cancer compared with 4–7 times per month when frequency was reported in their twenties, and 0.78 (0.69–0.89) when reported in their forties — roughly a 19–22% lower risk, and driven by low-risk disease. The widely quoted "33%" comes from Leitzmann 2004, an earlier analysis of this same cohort that the longer follow-up revised downward; Rider is the figure to use. The proposed mechanism (clearing prostatic secretions, reduced intraluminal stasis) is not established, and this is an association, not a demonstrated effect.

Cabeza de Baca et al. (Psychoneuroendocrinology, 2017) measured telomere length in 129 premenopausal women: those reporting sexual intimacy in the prior week had significantly longer telomeres — a direct biomarker of cellular aging — independent of relationship satisfaction and perceived stress. Correlational, but a notable longevity signal.

The finding above is only interesting if telomere length means something, and this is the study that says how much. Rode et al. (J Natl Cancer Inst, 2015) measured leukocyte telomere length in 64,637 people from two Danish general-population cohorts and followed them for up to 22 years, during which 7,607 died. Shorter telomeres tracked with higher mortality across the whole range (P for trend = 2×10⁻¹⁵), and people in the shortest tenth had a 40% higher rate of death from any cause than those in the longest (HR 1.40, 95% CI 1.25–1.57), with similar results for cancer and cardiovascular death. THE SAME PAPER IS ALSO THE REASON TO BE CAREFUL: when the authors used inherited telomere-shortening genotypes as an instrument — asking whether short telomeres CAUSE early death rather than accompany it — the association with all-cause mortality disappeared. So telomere length is a well-evidenced marker of biological ageing and a poor candidate for a lever you pull directly. Read it as a reading, not a target.

A meta-analysis of 12 prospective cohort studies following 36,744 men found erectile dysfunction associated with later cardiovascular disease. Compared with men without it, men with erectile dysfunction had about 48% higher risk of cardiovascular disease (RR 1.48, 95% CI 1.25-1.74), 46% higher risk of coronary heart disease, 35% higher risk of stroke and 19% higher all-cause mortality. The association persisted in the studies that controlled for age, BMI, blood pressure, diabetes, cholesterol and smoking, which the authors read as evidence that erectile dysfunction is probably an independent risk factor, not merely an early marker. One mechanism they cite is the "artery size hypothesis": the narrower penile arteries are obstructed earlier than the coronary arteries by the same burden of plaque, so symptoms can surface years before a cardiac event. The caveats matter — only 8 of the 12 studies reported cardiovascular events, with just 3 to 4 each covering the coronary, stroke and mortality outcomes; erectile dysfunction was mostly self-reported; results varied widely between studies (I² = 72.9%); and observational work cannot prove cause. If this is you, it is worth raising with a doctor as a heart question, not only a sexual one.

A meta-analysis of case-crossover studies asked whether sex acts as a short-term trigger for cardiac events. Only four of the fourteen pooled studies covered sexual activity, and across them episodic sexual activity was associated with a transiently elevated risk of myocardial infarction (RR 2.70, 95% CI 1.48–4.91) — the wide interval is the honest signal. The relative figure sounds alarming; the absolute one does not: the authors estimated the increase from one additional hour of physical or sexual activity per week at roughly 2 to 3 extra heart attacks per 10,000 person-years. The triggering association was weaker among people with higher habitual physical activity (interaction P = .04 for sexual activity and MI), so being regularly active appeared to blunt it. Case-crossover studies compare each person against themselves — they establish timing and association, not cause. If you have known heart disease, ask your doctor what is safe for you.

A meta-analysis of 17 studies found that passive body heating — a warm bath or shower 1–2 hours before bed (~40–42.5°C) — was associated with shorter time to fall asleep and improved sleep quality. The mechanism is thermoregulatory (warming the skin helps the body shed core heat into the natural pre-sleep temperature drop). Note: transdermal magnesium absorption from Epsom salts is not evidence-supported — the benefit is the warm water, not magnesium uptake.

A systematic review with meta-analysis found phototherapy (red and near-infrared light) was associated with modest improvements in muscle performance and post-exercise recovery markers. The effect is real but modest — not a dramatic accelerant.

A meta-analysis found massage after strenuous exercise was associated with reduced delayed-onset muscle soreness and lower markers of muscle damage. Most effective applied within ~2 hours post-exercise.

Meta-analyses associate foam rolling with short-term gains in range of motion and reduced perceived soreness. The mechanism is neural / pain-modulation (altered stretch tolerance and mechanoreceptor signalling) — not "fascial release" or lasting tissue change. A softball or lacrosse ball applies the same self-massage to smaller trigger points.

A systematic review and meta-analysis found voluntary slow breathing (~6 breaths/min) was associated with increased vagally-mediated heart rate variability — a marker of parasympathetic ("rest and digest") activity. A slow nasal walk is one easy way to practise it.

In randomized trials, yoga-nidra / non-sleep-deep-rest practice was associated with increased heart rate variability and reduced anxiety — markers of a parasympathetic, calmed state. (We do not claim it "restores dopamine" — that specific figure is not well supported.)

A controlled study found a brief 10–20 minute afternoon nap improved alertness and cognitive performance, while a 30-minute nap produced grogginess (sleep inertia) before any benefit. Keep naps short to avoid entering slow-wave sleep.

A meta-analysis of change-score data from 23 studies in healthy participants found small overall benefits from wearing compression garments after exercise (effect size 0.38). The clearest signal was recovery of strength, with large effects 2-8 hours after exercise (ES 1.14) and beyond 24 hours (ES 1.03), and the benefit was greatest following resistance exercise. Garment pressure and training status did not clearly change the outcome, though the authors note the data reported on both was sparse — so how tight a garment should be, and whether trained people respond differently, is still open. On this evidence, compression is best read as a small, strength-focused edge after lifting rather than a general recovery fix.

In a 12-week randomised trial, 21 physically active young men (average age 21) strength trained twice a week and did either 10 minutes of cold water immersion (10°C, waist-deep) or active recovery after every session. Strength and muscle mass increased more in the active recovery group. Isokinetic work (19%), type II muscle fibre cross-sectional area (17%) and myonuclei per fibre (26%) increased in the active recovery group but not in the cold water group. This is one small trial in young men, and it speaks only to cold immersion taken straight after resistance training — it says nothing against cold exposure on rest days, hours later, or for other goals.

An observational analysis of roughly 2 million nightly heart-rate-variability readings from more than 21,000 wearable users (Grosicki, Galpin and colleagues, Am J Physiol Heart Circ Physiol, 2026) found that higher night-to-night variability in HRV — the seven-day coefficient of variation — was associated with more alcohol, less physical activity, and shorter, less consistent sleep (all P < 0.001), with stronger associations for alcohol and sleep than for average HRV itself. At least five of seven nights were needed to estimate a weekly figure reliably. Because this is observational wearable data, these are associations rather than demonstrated causes. Disclosure: the study was funded by WHOOP, Inc., and most of its authors are WHOOP employees.

A 2024 study and 2020/2023 reviews found menstrual-cycle phase did not meaningfully affect muscle protein synthesis or resistance-training adaptation, with at most a trivial effect on performance. Consistent training adjusted by feel is better supported than syncing workouts to cycle phases.

In the luteal phase (second half of the cycle) resting energy expenditure rises slightly (about +6.9% sleeping energy expenditure, +0.27°C core temperature) and intake tends to rise (about +159 kcal, +6 g protein, +15 g carbohydrate vs the follicular phase). A small, real shift — eating a little more then is normal.

Sleep often gets lighter premenstrually; luteal-phase rises in core temperature and changes in REM are part of why — the same thermoregulatory reason a cool room and a warm bath before bed help (see Sleep).

Despite popular claims, menstrual-cycle phase does not meaningfully change overall fluid balance or plasma volume; the luteal phase does run slightly warmer. Hydrate to thirst, a little more in the heat.

For premenstrual psychological symptoms, a 2025 review of 31 RCTs found the most consistent benefit from vitamin B6 (about 50 mg/day or more), calcium (about 1000 mg/day or more), and zinc; evidence for magnesium, vitamin D, and multivitamins was insufficient. Food first; keep long-term B6 under about 50 mg/day.

Timing matters: a 2025 review found that during perimenopause, strength, endurance, and Tai Chi did not improve bone density or lean mass, whereas in early postmenopause, strength training plus walking did. High-intensity resistance and impact training (the LIFTMOR trial) also improved bone density and physical function in postmenopausal women with low bone mass. Train for strength throughout, but the bone-and-muscle payoff evidence is strongest after menopause.

Hormone therapy is the most effective treatment for hot flashes (about 75% reduction vs placebo) and improves sleep specifically in women who have vasomotor symptoms. It is a medical decision with trade-offs — discuss it with a clinician.

Whether to train fasted is unsettled: a 2025 meta-analysis of 28 RCTs in healthy adults found predictable acute metabolic differences (more fat use when fasted, higher glucose and insulin when fed) but no clear outcome winner, and women-specific outcome data is limited. Watch your own response rather than follow a rule.

A Cochrane review of 12 trials found exercise — roughly 45–60 minutes, three or more times a week, at any intensity — was associated with a clinically meaningful reduction in period-pain intensity of about 25mm on a 100mm scale versus no treatment. The authors graded the evidence low-quality, so this is the best available answer rather than a settled one.

Pooled across 15 randomised trials (717 women), exercise was associated with reduced premenstrual symptoms overall, and separately across psychological, physical and behavioural symptom groups. The trials disagreed with each other substantially and most carried a high risk of bias — worth doing, not proven.

In a randomised controlled trial of 74 women, eight weeks of mindfulness-based stress reduction was associated with markedly lower premenstrual symptom scores than the control group (96.4 vs 123.0). A single small study — enough to be worth testing on yourself, not enough to be a recommendation.

A meta-analysis of 9 studies found internal body temperature was higher in the luteal phase both before and after exercise in the heat, with no compensating change in sweat rate, mean skin temperature or exercise heart rate — consistent with a shifted thermoregulatory set point rather than a reduced ability to shed heat. Expect the same heat dose to cost more in the high-hormone half.

The Institute of Medicine sets iron intake for premenopausal women at 18mg/day against 8mg/day for men and postmenopausal women, precisely because of menstrual blood loss. Typical intake in women of reproductive age falls well short of it. Menstruation is a reason to think about iron — not about protein, which does not need to move.

A prospective multi-site study followed 259 physically active girls and women (mean age 18) and tracked physician-confirmed bone stress injuries; 28 of them (10.8%) sustained one. Three individual triad-related risk factors were each significantly associated with injury: 14.7% for training 12+ hours a week, 15.3% for BMI under 21, and 21.0% for low bone mass (DXA Z-score below -1.0). Risk factors in combination tracked with substantially higher rates: 29.7% for low bone mass plus 12+ hours a week of training (odds ratio 5.1, 95% CI 2.2-12.1), and 46.2% for high training volume plus a leanness-focused sport plus high dietary restraint (odds ratio 8.7, 95% CI 2.7-28.3). Not every triad-related factor was significant on its own, and the combined-factor estimates come from small subgroups with wide confidence intervals — this is an observational association in a modest, young, athletic sample, and it does not establish that the risk factors caused the injuries. If several of these describe you, that is worth raising with a sports medicine doctor.

In a small randomized laboratory trial, 29 young, regularly menstruating, habitually sedentary women of normal body composition each did two five-day stays at least two months apart, eating measured food while doing the same supervised exercise every day (15 kcal per kg of lean mass). Energy availability — food energy in, minus energy burned in exercise, expressed per kg of lean body mass — was set at 45 kcal per kg per day in one stay, and at 30, 20 or 10 in the other. Pulses of luteinizing hormone, part of the hormonal signalling that regulates the menstrual cycle, showed no detectable change at 30 kcal per kg of lean mass per day, while at the lower levels tested pulse frequency fell and amplitude rose. Read that number carefully: each level was run in only about a third of the women, so detecting nothing at 30 in roughly ten people is not proof that 30 is safe — and because the next level tested was 20, the real turning point sits somewhere between the two, unmeasured. This is where the widely quoted 30 kcal/kg figure comes from, and it is not a validated personal cut-off. Energy availability is a laboratory measure that needs measured lean mass and measured exercise energy: it is not a calorie target or an amount to eat. What was measured here was a hormone pulse pattern over five days in one phase of the cycle — not missed periods, bone health, fertility, or any long-term outcome. Under-fuelling relative to training is linked to disturbed cycle hormones, but menstrual changes have many possible causes, and that is a conversation for a doctor rather than a number to calculate for yourself.

A systematic review and multilevel meta-analysis pooled 8 non-randomised studies of 325 women (159 oral contraceptive pill users, 166 naturally menstruating non-users, average age 24) who did matched resistance training for 8 to 16 weeks. It found no significant difference between the groups in muscle growth (effect size 0.01, 95% CI -0.11 to 0.13) or strength (0.10, 95% CI -0.08 to 0.28). The power result (-0.04, 95% CI -0.93 to 0.84) came from only 3 of the 8 studies and was lower-body only; the authors call that model underpowered and say to read it with caution, so it is too imprecise to point either way. Nobody was assigned to the pill — the women chose it themselves — so the two groups may differ in other ways, and at roughly 17 women per group this is a small evidence base: read it as no difference detected, not as proof the pill makes none. Every included study looked at the pill specifically, not the hormonal IUD, implant, ring, patch or injection. The authors concluded there is no evidence-based rationale to advocate for or against pill use for women who lift, and that an individual approach — your own response to it, your reasons for taking it, your cycle history — fits better. Whether to be on it is a medical decision with trade-offs; discuss it with a clinician.

A systematic review (no meta-analysis) of 23 studies covering 669 female athletes aged 13–47 across 16 sports. Everyone included was training hard — more than 5 hours a week, or a VO₂ max above 45 — and had iron deficiency confirmed by a blood test (serum ferritin under 40 µg/L). In that group, iron deficiency was associated with endurance performance about 3–4% below athletes with adequate iron stores. Correcting a confirmed deficiency was associated with endurance improving 2–20% and maximal aerobic capacity improving 6–15% — but the aerobic result came only from studies of the most depleted athletes (ferritin under 16 µg/L), and the paper notes little effect once stores are above 25 µg/L. Strength and anaerobic power moved in both directions and mostly not significantly. Most studies had groups of 20 or fewer athletes and no results were pooled, so the individual figures are imprecise. None of this applies to women with normal iron stores. The paper's background cites prevalence estimates for iron deficiency in female athletes ranging from roughly 9% to 60%, depending on the population and the cut-off used. Iron status is a blood test, not a feeling — the authors advise athletes with low iron to work with a sports medicine practitioner or dietitian, and the doses used in these studies run far above everyday supplement levels.

A systematic review with meta-analysis pooled eight observational studies of female athletes and found urinary incontinence — any involuntary loss of urine, not only leaking during effort — reported by about 36% of them. The same review reported that athletes had a 177% higher rate of incontinence than sedentary women; that is a comparison between groups, not evidence that training causes leaking, and no confidence interval is published for either figure. Data like this also cannot separate training from age, body weight or previous childbirth. The authors propose that the repeated rise in intra-abdominal pressure during high-impact activity loads the pelvic floor. These are self-reported, cross-sectional figures pooled from studies published between 2000 and 2016 across a range of sports, so treat 36% as a rough signal that this is common rather than as your own odds. Common does not mean untreatable: pelvic floor muscle training is the usual first-line approach, and this is worth raising with a doctor or a pelvic health physiotherapist rather than managing alone with pads or by drinking less before sessions.

Relative Energy Deficiency in Sport (REDs) is the International Olympic Committee's term for a syndrome of health and performance problems seen in female AND male athletes exposed to low energy availability — which the consensus defines as inadequate energy intake in relation to exercise energy expenditure. The 2023 statement introduced a Physiological Model built to show the complexity of either problematic or adaptable low-energy-availability exposure, coupled with individual moderating factors: eating less than you burn is not automatically damaging, and which way it goes depends on the person and the exposure. It also introduced a Clinical Assessment Tool (version 2) to help detect and clinically diagnose REDs — built for practitioners, not a checklist to score yourself against. This is an expert panel's consensus synthesising the literature, not a trial or a systematic review. If your periods have stopped or turned irregular, or injuries keep stacking up, that is a reason to talk to a doctor or a sports dietitian — not a reason to eat less.

A systematic review with Bayesian meta-analysis by Refalo, Galpin and colleagues (PeerJ, 2025) screened 2,720 studies and pooled the 29 in which men and women completed the same resistance-training programme. Absolute increases in muscle size slightly favoured males (SMD 0.19, 95% HDI 0.11 to 0.28), but increases measured relative to each person's own starting size were similar between the sexes (0.69% difference, 95% HDI −1.50% to 2.88%). The absolute male advantage appeared in the upper body but not the lower. Type I fibre growth slightly favoured males, while Type II fibre growth was similar. The authors conclude the findings strengthen the understanding that women have a similar potential to build muscle as men, particularly when growth is measured relative to starting size. Sex was not randomised, so these are between-group comparisons rather than a causal test of sex itself.

A meta-analysis of 38 RCTs (149,051 participants) associated omega-3 with modestly lower cardiovascular mortality (about 7% lower) and fewer non-fatal heart attacks and coronary events; EPA alone outperformed EPA plus DHA. Caveat: higher-dose omega-3 slightly raised atrial-fibrillation risk — more is not always better.

Creatine is well-supported for building strength, lean mass, and recovery alongside resistance training. Brain and cognitive benefits are plausible but not proven — a 2024 EFSA panel found the cognition evidence inconclusive (methodological double-counting).

Zone 2 (a conversational pace) builds an aerobic base at low injury risk and is metabolically useful. The popular claim that it is uniquely optimal for mitochondria or fat oxidation is contested — a 2025 review argues higher intensities may do more, especially for non-elite trainees. Both matter; do not let easy cardio crowd out intensity. (Library record of the debate; the Zone 2 drawer stays focused on the practical case.)

A 2025 meta-analysis (11 RCTs, 3,177 people) found cold-water immersion may modestly help stress, sleep, and quality of life (time-dependent), with no significant immune benefit, a small and low-quality evidence base, and an acute rise in inflammation right after immersion. Practical caveat: do not ice right after lifting — it can blunt strength and muscle gains.

VITAL randomised 25,871 US adults (men 50 and over, women 55 and over) to 2,000 IU/day of vitamin D3 or placebo, in a two-by-two design that also tested omega-3, and followed them for a median of 5.3 years. Vitamin D did not reduce the primary endpoint, total invasive cancer of any type (hazard ratio 0.96, 95% CI 0.88-1.06), or major cardiovascular events (0.97, 0.85-1.12). All-cause mortality showed no detectable difference (0.99, 0.87-1.12) — but as a secondary endpoint its confidence interval still spans anything from a 13% reduction to a 12% increase, so read that as no evidence of benefit rather than proof of none. One signal did emerge: death from cancer trended lower (0.83, 0.67-1.02) and reached statistical significance in analyses that excluded the first two years of follow-up to allow for latency (0.75, 0.59-0.96) — suggestive, not definitive. No excess hypercalcemia, kidney stones or other adverse events were identified. Important limit: this recruited a general population, not people with documented deficiency — only about 13% of those with a measured level were below 20 ng/mL — so it says nothing about correcting a low measured level; if you think yours is low, testing and dosing are a conversation with your doctor.

A meta-analysis pooled 107 cohort studies — 4,838,825 people and 425,564 deaths — to re-test the familiar claim that light drinking is associated with lower mortality. Once the models adjusted for sampling variation, former-drinker bias (people who had quit drinking, often because they were already ill, sitting in the non-drinker comparison group), and other prespecified study-quality criteria, occasional drinking (more than 0 up to 1.3 g of ethanol per day; RR 0.96) and low-volume drinking (1.3–24 g/day; RR 0.93) showed no significant mortality benefit versus lifetime non-drinkers. Risk was nonsignificantly higher at 25–44 g/day (RR 1.05), and significantly higher at 45–64 g/day (RR 1.19) and at 65 g or more (RR 1.35). Female drinkers had significantly higher risk than female lifetime non-drinkers (RR 1.22). This pools observational cohorts rather than trials, so it cannot establish cause — the authors' point is that the apparent J-curve largely shrank once former-drinker bias and study quality were accounted for. If you drink heavily and are thinking about cutting back, that is worth a conversation with your doctor.

An umbrella review in the BMJ pooled 45 analyses drawn from 14 meta-analyses, covering 9,888,373 people. Higher ultra-processed food exposure was directly associated with 32 of the 45 outcomes examined. On the review's credibility scale, evidence was convincing for cardiovascular-disease-related mortality (risk ratio 1.50, 95% CI 1.37-1.63 — though GRADE quality for that particular result was very low) and for type 2 diabetes (risk ratio 1.12, 95% CI 1.11-1.13 per 10% increment in ultra-processed food intake, moderate quality). It was highly suggestive for all-cause mortality (risk ratio 1.21), depressive outcomes (hazard ratio 1.22), adverse sleep-related outcomes (odds ratio 1.41) and obesity (odds ratio 1.55). All of this is observational, and the evidence base is weak: only 4 of the 45 pooled analyses rated moderate quality under GRADE, 22 rated low and 19 very low. The pattern is broad and consistent, but it cannot show that processing itself is the cause.

Bathgate, Galpin and colleagues (Eur J Appl Physiol, 2018) studied a single pair of identical 52-year-old male twins — one with more than 30 years of endurance training, the other with no consistent exercise. The trained twin had a VO2max 12.4 ml/kg/min higher (47.5 against 35.1), 8.6 percentage points less body fat, and a far more slow-twitch muscle: roughly 94% MHC I fibres against about 40% in his brother, a gap of 55 percentage points or about 2.4 times as many. He also had lower resting heart rate, blood pressure, cholesterol, triglycerides and glucose — but lower muscle size and strength. Two limits travel with it: this is one twin pair with no statistics, and the authors themselves note the body-composition difference may not be down to exercise alone, since the untrained twin also ate slightly more than he burned, which they estimate could account for around 7 kg over 30 years.

The claim that metformin extends life began in St Petersburg: in 2008 Vladimir Anisimov's lab reported that female outbred SHR mice given metformin in their water had a 37.8% longer mean lifespan — with no change in tumour incidence. That number travelled the world; what it rests on did not. A US National Institute on Aging study found a modest lifespan gain in male mice only at 0.1% of diet, and a ten-fold higher dose was toxic. The NIA's three-site Interventions Testing Program — genetically diverse mice, both sexes, the strongest test that exists — reported that metformin alone "did not significantly extend lifespan". And a 2025 meta-analysis of 911 effect sizes across eight vertebrate species, including Anisimov's own papers, is titled for its finding: rapamycin, not metformin, mirrors the lifespan extension of dietary restriction. All of this is in animals; none of it is a verdict on metformin for people with diabetes, who take it for a different reason. It is a verdict on the headline.